Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Young Lu

Orthopaedic Surgery of the Spine Wilmington, NC Medical Doctor

NPI 1366861882 CMS profile 4220603

2716 Ashton Dr, Wilmington, NC 28412

Open in the dashboard

General payments

$7,917

105 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Young Lu of Wilmington, NC is reported in the CMS Open Payments database as having received $7,917 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,380 12
2024 General $1,661 26
2023 General $2,209 30
2022 General $1,200 19
2021 General $1,206 13
2020 General $263 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Young Lu
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Young Lu were reported at $1,380. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Young Lu Orthopaedic Surgery of the Spine median Middle half National median
2019 $0 $2,106 $337–$18,608 $163
2020 $263 $1,213 $156–$15,082 $114
2021 $1,206 $1,834 $271–$15,617 $132
2022 $1,200 $2,015 $320–$17,036 $149
2023 $2,209 $1,925 $336–$14,599 $160
2024 $1,661 $2,110 $341–$12,483 $164
2025 $1,380 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $2,822 46 payments
  2. Stryker Corporation $2,336 20 payments
  3. NuVasive, Inc. $1,579 22 payments
  4. Globus Medical, Inc. $402 5 payments
  5. Seaspine Orthopedics Corporation $204 3 payments
  6. TrackX Technology, LLC $156 2 payments
  7. Sanara MedTech Inc. $127 1 payment
  8. Galderma Laboratories, L.P. $125 1 payment
  9. Orthofix Medical, Inc. $111 2 payments
  10. Cerapedics, Inc. $21 1 payment
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,113 80 payments
  2. Travel and Lodging $3,804 25 payments
Products named General payments · program years 2020–2025
  1. MAZOR X SYSTEM $1,783 22 payments
  2. XLIF $1,637 19 payments
  3. CASCADIA INTERBODY SYSTEM $884 3 payments
  4. EVEREST SPINAL SYSTEM $793 7 payments
  5. CAPRI CORPECTOMY CAGE SYSTEM $201 2 payments
  6. O-ARM $166 7 payments
  7. AQUAMANTYS(TM) $155 6 payments
  8. SPINEMAP $154 1 payment
  9. Manta Ray $133 1 payment
  10. MARS $131 1 payment
  11. Other $1,729 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

844

Median for Orthopedic Surgery: 203

Drug cost

$3,908

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 364 $1,174
Gabapentin Generic 95 $637
Methylprednisolone Generic 110 $594
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 50 $439
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 49 $336
Methocarbamol Generic 62 $239
Ondansetron Hcl Generic 52 $238
Celecoxib Generic 12 $121
Cyclobenzaprine Hcl Generic 17 $72
Tramadol Hcl Generic 20 $45

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$175,243

Medicare's payments for the services billed

Medicare patients

506

Average age 74

Services billed

1,571

294 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Depression 29%
Ischemic heart disease 27%
Chronic kidney disease 24%
Cancer 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record